Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02274987 · ClinicalTrials.gov registry record · NA
Molecular Profiling for Individualized Treatment Plan for DIPG
A NA study of Diffuse Intrinsic Pontine Glioma (DIPG), sponsored by University of California, San Francisco.
- Completed
- Registry status
- NA
- Development phase
- 38
- Enrollment target
- 5
- Study locations
NCT02274987: Completed NA study of Diffuse Intrinsic Pontine Glioma (DIPG), sponsored by University of California, San Francisco.
NCT02274987 is a NA study of Diffuse Intrinsic Pontine Glioma (DIPG) that has completed, run by University of California, San Francisco. The registered enrollment target is 38 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02274987, a NA study of Diffuse Intrinsic Pontine Glioma (DIPG), has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a single arm multi-center pilot trial within the Pacific Pediatric Neuro-Oncology Consortium (PNOC). The current study will use a new treatment approach based on each patient's tumor genomic profiling consisting of whole exome sequencing and RNA sequencing as well as predictive modeling.
Conditions Studied
Interventions
- OTHER Specialized tumor board recommendation
- RADIATION Standard radiation therapy
Study Locations (5)
California
- Rady Children's Hospital - San Diego
- University of California, San Francisco - San Francisco
District of Columbia
- Children's National Medical Center - Washington D.C.
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2014-09-16 |
| Est. Completion | 2019-02-24 |
| Phase | NA |
What the finished NCT02274987 record still lists
NCT02274987 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Diffuse Intrinsic Pontine Glioma (DIPG) appearing as the primary indexed condition, and to 2 interventions - of which Specialized tumor board recommendation is the first listed.
NCT02274987 lists 5 locations in 4 states (California, District of Columbia, Illinois).
Frequently Asked Questions
What is clinical trial NCT02274987 about?
NCT02274987 is a clinical study titled "Molecular Profiling for Individualized Treatment Plan for DIPG". This is a single arm multi-center pilot trial within the Pacific Pediatric Neuro-Oncology Consortium (PNOC). The current study will use a new treatment approach based on each patient's tumor genomic profiling consisting of whole exome sequencing and RNA sequencing as well as predictive modeling.
What is the current status of trial NCT02274987?
This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2014-09-16. Estimated completion is 2019-02-24.
What conditions does trial NCT02274987 study?
This clinical trial studies the following conditions: Diffuse Intrinsic Pontine Glioma (DIPG).
What interventions are being tested in trial NCT02274987?
The interventions under investigation include: Specialized tumor board recommendation (OTHER), Standard radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT02274987?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02274987 being conducted?
This trial has 5 study locations across California, District of Columbia, Illinois, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Intrinsic Pontine Glioma (DIPG)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02274987's enrollment target sits among peer trials
38 1538th of 2000 higher than 461 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI